OUR MISSION

Our mission is
to help pets live longer, healthier, and happier lives

Our four-legged family members are living longer than ever, bringing us much joy. Unfortunately, with this longer life span, our furry friends are now suffering from more cancers and other diseases of chronic inflammation — just like us.
 
 

OUR LEAD PRODUCT

ElenaVet®
is a gene therapy that enhances the body's
anticancer immune response.

In our comparative medicine studies, we saved 10 out of 11 dogs with breast cancer and precluded or delayed the metastatic process in dogs with melanoma. We observed similar results with cats.

Read more

ElenaVet also reduces chronic inflammation, which causes not only cancer but other serious diseases such as osteoarthritis, Inflammatory bowel disease (IBD), and chronic dermatologic issues — as well as age-associated declines. Our goal is to tackle these diseases one by one, starting with cancer.

Less

 
 

OUR LEAD PRODUCT

ElenaVet®
is a gene therapy that enhances the body's
anticancer immune response.

In our comparative medicine studies, we saved 10 out of 11 dogs with breast cancer and precluded or delayed the metastatic process in dogs with melanoma. We observed similar results with cats.

Read more

ElenaVet also reduces chronic inflammation, which causes not only cancer but other serious diseases such as osteoarthritis, Inflammatory bowel disease (IBD), and chronic dermatologic issues — as well as age-associated declines. Our goal is to tackle these diseases one by one, starting with cancer.

Less


PATIENT
TESTIMONY

If your pet is suffering from breast cancer, oral melanoma, osteoarthritis or IBD, we may be able to help you right away - free of charge - by partnering with your veterinarian.

PATIENT TESTIMONY If your pet is suffering from breast cancer, mouth melanoma, osteoarthritis or IBD, we may be able to help you right away—free of charge—by partnering with your veterinarian. Play Video

Sign up here to receive updates about our breakthrough
pet cancer therapy



    Sign up here to receive updates about our breakthrough
    pet cancer therapy


       

      OUR STORY

      A biotech startup
      - with an established track record.

      CureLab Veterinary, a subsidiary of CureLab Oncology, was created in November 2020 to save lives and improve the welfare of cats, dogs, and horses.

      Read more

      Our parent company, which is focused solely on human immune-oncology, was established in 2012 by experienced scientists and business experts. Our advisory board includes a Nobel Laureate and a recent member of the US president’s cabinet. Our work on readying our therapy for human clinical trials has shown that our product is safe and effective in dogs and cats.

      Less

       
       



      CANCER

      How does
      ElenaVet work?

      Why does your pet have a cancer?

      Both pets and humans have pre-cancer and even cancer cells, but these bad cells can do no harm unless the tissue surrounding them allows the formation of primary tumors and the potential for metastasis.

      Read more

      Often, pre-cancer cells can form tumors when a surrounding tissue is in a state of chronic inflammation. Additionally, tumors use chronic inflammation within the tumor to suppress the body’s natural anticancer immune response to resist treatments. Administering ElenaVet reduces chronic inflammation. This means it has excellent anti-cancer potency and synergizes well with other anti-cancer therapies.

      Less




      A tumor is not a bag full of cancer cells. Cancer cells cannot survive without the support of tumor stroma cells. ElenaVet alters tumor stroma making it less supportive for cancer cells. For example, a tumor prognosis is correlated with an expression of a protein called α-SMA. Our product reduced the tumor risk modulating α-SMA ‘s expression level.
       

      CANCER

      How does
      ElenaVet work?

      Why does your pet have a cancer?

      Both pets and humans have pre-cancer and even cancer cells, but these bad cells can do no harm unless the tissue surrounding them allows the formation of primary tumors and the potential for metastasis.

      Read more

      Often, pre-cancer cells can form tumors when a surrounding tissue is in a state of chronic inflammation. Additionally, tumors use chronic inflammation within the tumor to suppress the body’s natural anticancer immune response to resist treatments. Administering ElenaVet reduces chronic inflammation. This means it has excellent anti-cancer potency and synergizes well with other anti-cancer therapies.

      Less

      A tumor is not a bag full of cancer cells. Cancer cells cannot survive without the support of tumor stroma cells. ElenaVet alters tumor stroma making it less supportive for cancer cells. For example, a tumor prognosis is correlated with an expression of a protein called α-SMA. Our product reduced the tumor risk modulating α-SMA ‘s expression level.
       
       

      ELENAVET

      How does
      ElenaVet work?

      ElenaVet corrects the tumor microenvironment surrounding cancer cells, making it more favorable for anti-cancer immunity.
      ElenaVet changes the tumor structure itself, making it harder for metastatic cells to exit the tumor and form new remote lesions.

      Read more

      The grade of a tumor — the cancer grade — is an indication of how quickly it is likely to grow and spread. Tumors of higher grades are more resistant to treatments. Our ElenaVet prototype reverted/reduced the tumor grade in five out of six canine mammary cancers; and in one case out of six, the tumor was reverted to a non-cancerous state.

      Less




      The extracellular matrix in a tumor is predominantly formed of collagen Type 1. Treatment with ElenaVet shifts it from Type 1 to Type 3. This shift in collagen type is important as Lymphocytes circulating in the blood use collagen Type 3 more efficiently to penetrate the tumor and attack it. Metastatic cells have a harder time exiting the tumor if collagen Type 3 is present...
       
       

      ELENAVET

      How does
      ElenaVet work?

      ElenaVet corrects the tumor microenvironment surrounding cancer cells, making it more favorable for anti-cancer immunity.
      ElenaVet changes the tumor structure itself, making it harder for metastatic cells to exit the tumor and form new remote lesions.

      Read more

      The grade of a tumor — the cancer grade — is an indication of how quickly it is likely to grow and spread. Tumors of higher grades are more resistant to treatments. Our ElenaVet prototype reverted/reduced the tumor grade in five out of six canine mammary cancers; and in one case out of six, the tumor was reverted to a non-cancerous state.

      Less

      The extracellular matrix in a tumor is predominantly formed of collagen Type 1. Treatment with ElenaVet shifts it from Type 1 to Type 3. This shift in collagen type is important as Lymphocytes circulating in the blood use collagen Type 3 more efficiently to penetrate the tumor and attack it. Metastatic cells have a harder time exiting the tumor if collagen Type 3 is present...
       
       

      ELENAVET

      Non-cancer
      diseases

      What do osteoarthritis, inflammatory bowel disease, chronic dermatologic issues, and age-associated declines have in common? All of them are diseases of chronic inflammation.

      ElenaVet reduces chronic inflammation in the most comprehensive way. It lowers pro-inflammatory cytokines and increases anti-inflammatory ones, thereby dramatically reducing overall inflammation.

      Read more

      What happens when you cut your finger or catch a cold?
      Cells and tissues “scream for help” — sending out pro-inflammatory cytokines. When the danger is over, anti-inflammatory cytokines calm the tissue down.
      And what if the body doesn’t check the pro-inflammation process?
      Then we have a constant release of pro-inflammatory cytokines, causing chronic inflammation.
      What’s wrong with current anti-inflammatory treatments?
      They either target one specific proinflammatory cytokine or are highly toxic.
      ElanaVet has neither of these drawbacks.

      Less


      Instead of interfering with a particular cytokine, ElenaVet restores balance in the cells secreting them.
       
       

      ELENAVET

      What is
      ElenaVet?

      ElenaVet is a plasmid (supercoiled circular DNA) in which we have inserted a gene-encoding protein p62/SQSTM1.
      Plasmids constitute a main trend in a new generation of biomedicine.
      When injected into a patient, ElenaVet enters cells at the site of administering as well as in the bone marrow, and makes the cells it encodes produce p62 protein, which leads to multiple physiological outcomes.

      Read more

      Plasmids manufacturing is now efficient and highly scalable allowing for a price that is accessible to the general public which will result in helping tens of thousands of animals. If kept frozen, their shelf life is more than six years. Their regulatory approval process is straightforward. And the current dosage form is a simple intramuscular injections.

      Less


      Manufacturing is outsourced to a leading contract manufacturing partner experienced with USDA and FDA regulations.
       
       

      ELENAVET

      From laboratory
      to your veterinary clinics

      Partnering

      If you are an academic or private veterinary clinic, be among the leaders joining our clinical research programs for the latest therapy against cancer, osteoarthritis and inflammatory bowel disease. Your patient deserves to be included in the latest, cutting-edge study.

      Today, you can join our comparative medicine studies for breast cancer, melanoma, osteoarthritis, inflammatory bowel disease, chronic dermatitis and anti-aging.

      Please contact us:

      partnering@cure4pets.com

      +1-410-212-8962

      or:

      Click here


      We will provide you with the product and we will publish the results together.
       
       

      ELENAVET

      From laboratory
      to your veterinary clinics

      Partnering

      If you are an academic or private veterinary clinic, be among the leaders joining our clinical research programs for the latest therapy against cancer, osteoarthritis and inflammatory bowel disease. Your patient deserves to be included in the latest, cutting-edge study.

      Today, you can join our comparative medicine studies for breast cancer, melanoma, osteoarthritis, inflammatory bowel disease, chronic dermatitis and anti-aging.

      Please contact us:

      partnering@cure4pets.com

      +1-410-212-8962

      or:

      Click here


      We will provide you with the product and we will publish the results together.
       
       

      ELENAVET

      Regulatory

      We will pursue a regulatory approval through the USDA, which will be much faster and less costly than through the FDA.

      Read more

      Official USDA-controlled studies of application of ElenaVet to canine breast cancer, melanoma and feline breast cancer are expected to begin in 2021. Anticipated conditional licensure within 24 months. The company has secured assistance of an experienced regulatory group formed by former USDA specialists.

      Less

       
       

      ELENAVET

      Regulatory

      We will pursue a regulatory approval through the USDA, which will be much faster and less costly than through the FDA.

      Read more

      Official USDA-controlled studies of application of ElenaVet to canine breast cancer, melanoma and feline breast cancer are expected to begin in 2021.
      Anticipated conditional licensure within 24 months.
      The company has secured assistance of an experienced regulatory group formed by former USDA specialists.

      Less

       
       


      TEAM

      Management

      Alexander Shneider, Ph.D.

      Founder, Chairman of the Board, Interim CEO
      Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for the journals Aging and Cell Cycle; advisor at We Fund Health. Achievements and activities include drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.

      Robert Devlin, DVM, MBA

      Executive Consultant
      Rob progressed from a practicing veterinarian to an executive director of veterinary science division to a seasoned VP of business development. Proven US and international track record in operations management, online and multichannel B2B and B2C sales within the animal health market, working with and developing US CMO vendors as well as distribution channels, spokespeople, and market KOLs, and establishing pricing models.

      Jason Payne, MBA (finance)

      CFO
      Progressing from a financial analyst to a CFO, Jason acquired comprehensive experience including planning and directing execution of day-to-day accounting and financial management initiatives (financial planning, forecasting, budgeting, variance analysis, fundraising, and KPI setting/achievement tracking aimed at eliminating risks and reducing costs), preparing reports for recording of assets, liabilities, P&L, corporate tax filing.

      Vlad Gabai, Ph.D.

      VP of R&D
      Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.

      Read more

      Franco Venanzi, Ph.D.

      Director of Basic Research
      Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where he was Head of the Translational Biology Laboratory; 20 years of service as editor-in-chief, editorial board member and a reviewer for vaccination and immunobiology journals.

      Stephen Spector

      VP of Strategic BD
      Steve past experience includes online B2B & B2C marketing & sales of Techmira Corp., marketing patented teeth-cleaning products for pets and pain-reducing anti-inflammatory devices.

      Tim Cox

      PR consultant
      25 years of successful PR and brand-building experience for technology and biotech companies. Defined and executed the PR campaign for the launch of Embrace Pet Insurance. Formerly brand marketing at Apple.

      Ilya Lapshin

      JD – Legal Counsel
      18 years of legal experience in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Between a double major at MIT, physics with

      Less

       


      TEAM

      Advisory Board

      B. Duncan X. Lascelles

      BSc, BVSC, PhD, FRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
      NC State University, College of Veterinary Vedicine
      Professor of Surgery and Pain Management
      Director, Translational Research in Pain [TRiP] Program
      Director, Comparative Pain Research and Education Center

      Jörg M. Steiner

      Med.vet., Dr.med.vet., PhD, DACVIM-SAIM, DECVIM-CA, AGAF
      Texas A&M College of Veterinary Medicine & Biomedical Sciences University Distinguished Professor
      Small Animal Internal Medicine
      Dr. Mark Morris Chair in Small Animal Gastroenterology and Nutrition
      Director, Gastrointestinal Laboratory

      Zachary M. Wright

      DVM DACVIM (oncology)
      Chair of the VCA Pet CancerCare Alliance
      Medical Director-VCA Animal Diagnostic Clinic

      Keith Richter

      DVM, DACVIM
      Previously a Professor at the Cornell University College of Veterinary
      Medicine, Hospital Director of the Veterinary Specialty Hospital, Chief
      Medical Office of Ethos Veterinary Health, President and Board of Regents
      Member of the Comparative Gastroenterology Society, Board of Regents
      Member of American College of Veterinary Internal Medicine.

      Ross H. Palmer

      DVM, MS, DACVS
      Colorado State University
      Veterinary Medical Center
      Department Of Clinical Sciences
      Professor
      Associate Director Of Education at Translational Medicine
       


      TEAM

      Advisory Board

      B. Duncan X. Lascelles

      BSc, BVSC, PhD, FRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
      NC State University, College of Veterinary Vedicine
      Professor of Surgery and Pain Management
      Director, Translational Research in Pain [TRiP] Program
      Director, Comparative Pain Research and Education Center

      Jörg M. Steiner

      Med.vet., Dr.med.vet., PhD, DACVIM-SAIM, DECVIM-CA, AGAF
      Texas A&M College of Veterinary Medicine & Biomedical Sciences University Distinguished Professor
      Small Animal Internal Medicine
      Dr. Mark Morris Chair in Small Animal Gastroenterology and Nutrition
      Director, Gastrointestinal Laboratory

      Zachary M. Wright

      DVM DACVIM (oncology)
      Chair of the VCA Pet CancerCare Alliance
      Medical Director-VCA Animal Diagnostic Clinic

      Keith Richter

      DVM, DACVIM
      Previously a Professor at the Cornell University College of Veterinary
      Medicine, Hospital Director of the Veterinary Specialty Hospital, Chief
      Medical Office of Ethos Veterinary Health, President and Board of Regents
      Member of the Comparative Gastroenterology Society, Board of Regents
      Member of American College of Veterinary Internal Medicine.

      Ross H. Palmer

      DVM, MS, DACVS
      Colorado State University
      Veterinary Medical Center
      Department Of Clinical Sciences
      Professor
      Associate Director Of Education at Translational Medicine
       
       

      INVESTORS

      Download our One-Pager
      investor prospectus

      Play Video
       

      INVESTORS

      Market
      size

       
       
       
       
       
       
       
       
       
       
       


      FAST FACTS

      Anticipated cost per a course of treatment

      $ 1.5-3K

      Anticipated profit per a course of treatment

      $ 0.5-1K

       
       


      FAST FACTS

      The global animal health market size by 2028

      USD 74.5 billion

      CAGR of 5.9%

      Traditional cancer care in dogs:

      • $ 150-600 per dose of chemotherapy
      • $ 1,000-6,000 for a radiation protocol
       
       


      FAST FACTS

      The global animal health market size by 2028

      USD 74.5 billion

      CAGR of 5.9%

      Traditional cancer care in dogs:

      • $ 150-600 per dose of chemotherapy
      • $ 1,000-6,000 for a radiation protocol
       

      IP

      CureLab
      Oncology Inc.

      has granted to its subsidiary CureLab Veterinary Inc.
      an exclusive worldwide license
      for application of its existing
      and future IP to cats, dogs, and horses.





       

      Oncology patents




      Read more

      Patent Granted

      Australia
      Chile
      Russia
      Belarus
      Belgium
      Switzerland
      Lichtenstein
      Germany
      Spain
      France
      UK
      Ireland
      Italy
      Luxembourg
      Netherlands
      Hong Kong
      Japan
      South Korea
      Mexico
      Singapore
      USA

      Patent Application Pending

      Canada
      India
      USA

      Less


      Anti-inflammation patents




      Read more

      Patent Granted

      Australia
      Hong Kong
      Japan
      Singapore
      Belgium
      Switzerland
      Lichtenstein
      Germany
      France
      UK
      Luxembourg
      Monaco
      Netherlands
      Japan
      South Korea
      Mexico
      Singapore
      USA

      Patent Application Pending

      Canada
      China
      India
      South Korea
      USA
      Italy
      Spain

      Less

       
       

      IP

      CureLab
      Oncology Inc.

      has granted to its subsidiary CureLab Veterinary Inc.
      an exclusive worldwide license
      for application of its existing
      and future IP to cats, dogs, and horses.




       

      Oncology patents




      Read more

      Patent Granted

      Australia
      Chile
      Russia
      Belarus
      Belgium
      Switzerland
      Lichtenstein
      Germany
      Spain
      France
      UK
      Ireland
      Italy
      Luxembourg
      Netherlands
      Hong Kong
      Japan
      South Korea
      Mexico
      Singapore
      USA

      Patent Application Pending

      Canada
      India
      USA

      Less


      Anti-inflammation patents




      Read more

      Patent Granted

      Australia
      Hong Kong
      Japan
      Singapore
      Belgium
      Switzerland
      Lichtenstein
      Germany
      France
      UK
      Luxembourg
      Monaco
      Netherlands
      Japan
      South Korea
      Mexico
      Singapore
      USA

      Patent Application Pending

      Canada
      China
      India
      South Korea
      USA
      Italy
      Spain

      Less